Harvest Integrated Research Organization (HiRO), a global contract research organization (CRO), has acquired Courante Oncology, a U.S.-based full-service clinical research provider specializing in oncology product development. HiRO is a boutique CRO serving the Asia-Pacific region. Its acquisition of Courante Oncology extends the organization’s presence into the U.S. market.

Courante Oncology brings more than 25 years of experience in the drug development industry. The company’s expertise spans all aspects of phase 1-3 clinical trials, ranging from initial feasibility studies and protocol development to site monitoring and closeout visits.

“We are thrilled to welcome Courante Oncology into the HiRO family,” said Dr. Karen Chu, Founder and CEO of HiRO. “This acquisition allows us to leverage Courante’s extensive experience in oncology trials and enhance our capabilities in managing global studies. Together, we strive to deliver best-in-class cross-border solutions and relentless accountability that set us apart in the demanding clinical trial landscape. Our focus remains on accelerating the delivery of innovative medicines with simple, rapid, cost-effective clinical research solutions across the commercialization pathway.”

“This marks an exciting chapter for Courante as we join forces with HiRO,” said Sheri Smith, President of Courante Oncology. “We are excited to join the HiRO family and collaborate closely with their team. This integration will enable us to further expand our service offerings and functions into the U.S. and beyond. We look forward to collaborating with our clients, to deliver effective, streamlined clinical trial solutions that meet and exceed their expectations.”